High expression of TRAF4 in hepatocelullar carcinoma as an independent negative survival and recurrence predictor

被引:0
作者
Ru-Cui Yu [1 ,2 ,3 ]
Ping-Sheng Fan [3 ]
Wei Wang [4 ]
Wei Jia [4 ]
机构
[1] School of Clinical Medicine, Shan Dong University
[2] Department of Chinese Medicine Oncology, Anhui Provincial Hospital
[3] The Cancer Hospital of Anhui Province,Provincial Hospital of Anhui Medical University
[4] Department of Medical Oncology, Anhui Provincial Hospital, Anhui Medical University
关键词
TRAF4; Hepatocellular carcinoma; Angiogenesis; Prognosis;
D O I
暂无
中图分类号
R735.7 [肝肿瘤];
学科分类号
100214 ;
摘要
Objective: To identify potential tumor markers for the development and recurrence of hepatocelullar carcinoma(HCC), this research studied the relationship between the expression of the tumor necrosis factor receptor-associated factor 4(TRAF4) and tumor angiogenesis together with its survival time of HCC patients. Methods: The expressions of TRAF4,vascular endothelial growth factor and CD34 were performed upon 90 patients with curative liver resection between August 2006 and November 2009 by immunohistochemical method in locally advanced HCC and adjacent non-tumoral liver. The expression of TRAF4 was determined by the Spearman rank correlation. Their prognostic factors on disease free survival(DFS) and overall survival(OS) were guaranteed by Kaplan-Meier and Cox regression analyses. The detection of the levels of vascular endothelial growth factor and CD34 was fulfilled in 90 cases of HCC. Results: TRAF4 expression was both significantly higher in HCC than in surrounding non-tumor tissues(57.8% vs. 22.2 %; P<0.001) and significantly correlated with tumor size and tumor staging. High TRAF4 was correlated with reduced DFS rate(P=0.001) and overall OS rate(P<0.001) and were displayed in Kaplan-Meier survival analysis. Conclusions: TRAF4 is involved with multifarious clinicopathologic features.TRAF4 expression, as an independent adverse prognostic factor, DFS and OS in HCC, is associated with increased tumor angiogenesis. The combined detection of TRAF4 in locally advanced HCC is a trustworthy predictive factor for the tumor development and recurrence.
引用
收藏
页码:68 / 72
页数:5
相关论文
共 11 条
[1]  
New advances in hepatocellular carcinoma[J]. Sonia Pascual,Iván Herrera,Javier Irurzun. World Journal of Hepatology. 2016(09)
[2]  
TRAF4 mediates activation of TGF-β signaling and is a biomarker for oncogenesis in breast cancer[J]. ZHOU Fang Fang,LI Fang,XIE Feng,ZHANG Zheng Kui,HUANG Hui Zhe,ZHANG Long. Science China(Life Sciences). 2014(12)
[3]   Emerging Trends in Hepatocellular Carcinoma Incidence and Mortality [J].
Njei, Basile ;
Rotman, Yaron ;
Ditah, Ivo ;
Lim, Joseph K. .
HEPATOLOGY, 2015, 61 (01) :191-199
[4]   Review of angiogenesis in hepatocellular carcinoma [J].
Muto, Jun ;
Shirabe, Ken ;
Sugimachi, Keishi ;
Maehara, Yoshihiko .
HEPATOLOGY RESEARCH, 2015, 45 (01) :1-9
[5]  
Hepatocellular cancer: how to expand safely inclusion criteria for liver transplantation[J] . Quirino Lai,Jan P. Lerut. Current Opinion in Organ Transplantation . 2014 (3)
[6]   TRAF4 Promotes TGF-β Receptor Signaling and Drives Breast Cancer Metastasis [J].
Zhang, Long ;
Zhou, Fangfang ;
de Vinuesa, Amaya Garcia ;
de Kruijf, Esther M. ;
Mesker, Wilma E. ;
Hui, Li ;
Drabsch, Yvette ;
Li, Yihao ;
Bauer, Andreas ;
Rousseau, Adrien ;
Sheppard, Kelly-Ann ;
Mickanin, Craig ;
Kuppen, Peter J. K. ;
Lu, Chris X. ;
ten Dijke, Peter .
MOLECULAR CELL, 2013, 51 (05) :559-572
[7]   Hepatocellular carcinoma [J].
Forner, Alejandro ;
Llovet, Josep M. ;
Bruix, Jordi .
LANCET, 2012, 379 (9822) :1245-1255
[8]   Predictors of Survival After Resection of Early Hepatocellular Carcinoma [J].
Nathan, Hari ;
Schulick, Richard D. ;
Choti, Michael A. ;
Pawlik, Timothy M. .
ANNALS OF SURGERY, 2009, 249 (05) :799-805
[9]   SPARC and Hevin expression correlate with tumour angiogenesis in hepatocellular carcinoma [J].
Lau, C. P-Y ;
Poon, R. T-P ;
Cheung, S-T ;
Yu, W-C ;
Fan, S-T .
JOURNAL OF PATHOLOGY, 2006, 210 (04) :459-468
[10]   Des-gamma carboxyprothrombin can differentiate hepatocellular carcinoma from nonmalignant chronic liver disease in American patients [J].
Marrero, JA ;
Su, GL ;
Wei, W ;
Emick, D ;
Conjeevaram, HS ;
Fontana, RJ ;
Lok, AS .
HEPATOLOGY, 2003, 37 (05) :1114-1121